Human term placenta a new abundant source of hematopoietic cellsJune 25, 2009Investigators at Children's Hospital Oakland Research Institute, Oakland, California found a way to obtain large numbers of hematopoietic stem cell from human term placenta. The results, which appear in the July 2009 issue of Experimental Biology and Medicine, describe detailed report on quantification, characterization, engraftment capacity, and most importantly, practical way to obtain hematopoietic stem cells from placenta in numbers that are several-fold higher than could be obtained from cord blood. The research team, Dr. Vladimir Serikov, MD, PhD, D.Sci, Assistant Staff Scientist, Catherin Hounshell, a research associate, Sandra Larkin, a research associate, Mr. William Green, student, Dr. Hurokazy Ikeda, MD, Visiting Scientist, Dr. Mark Walters, Medical Director of Children's Hospital Oakland Hematology and Oncology Programs, and Dr. Frans Kuypers, Senior Scientist, performed studies in human term placentas, human cord blood, and immunodeficient mice. Dr. Serikov said, that the fact the human term placenta is a hematopoietic organ was reported by our team for the first time more then a year ago, and this year this finding was confirmed by UCSF scientists headed by Dr. S. Fisher. In this report, said Dr. Serikov, we demonstrate for the first time that human placentas could provide abundant amounts of CD34+ CD133+ colony-forming cells, as well as other primitive hematopoietic progenitors, suitable for transplantation in humans. The total amount of live hematopoitic stem cells, or colony-forming units in culture that could be obtained from placentas was an order of magnitude larger than the number of hematopoietic stem cells obtained from cord blood from the same source. Hematopoietic stem cells which maintain their differentiation capacity, as well as stromal stem cells that support long-term culture of hematopoietic cells, can be harvested from perfusate of placenta following CXCR4 receptor blockade, said Dr. F. Kuypers. Importantly, live HPCs can similarly be obtained from whole cryopreserved placentas. Cells derived from placental tissue differentiated into all blood lineages in vitro. Animal experiments further demonstrated successful engraftment of placenta-derived HSC, which reconstituted hematopoiesis in immunodeficient mice. In summary, said Dr. F. Kuypers, our results indicate for the first time that human term placenta is a high capacity source of live and functional hematopoietic stem cells. By using placental circulation and stem cell receptor blockade an abundant amounts of hematopoietic stem cell could be easily obtained in sterile conditions by non-destructive methods. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "the outstanding importance of these results for practical hematology is determined by the fact that total number of stem cells that can be harvested from cord blood limits the efficacy of this stem cell source for transplants only to small children. These novel findings demonstrate that placenta may provide a source of autologous stem cells sufficient for reconstitution of hematopoiesis in adult patients. Use of methods to obtain hematopoietic cells from placenta, developed by Dr. Serikov and Dr. Kuypers as augumentation of cord blood-based therapy or replacement of bone marrow for transplantation will dramatically change whole field of transplantology." Society for Experimental Biology and Medicine |
|||||||||||||||||||||
| Related Hematopoietic Current Events and Hematopoietic News Articles Scientists successfully reprogram blood cells Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome. Immune therapy can protect against or treat later lymphoma Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection. Immunotherapy demonstrates long-term success in treating lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). MDC scientists show how hematopoietic stem cell development is regulated During cell division, whether hematopoietic stem cells (HSCs) will develop into new stem cells (self-renewal) or differentiate into other blood cells depends on a chemical process called DNA methylation. New research strategy for understanding drug resistance in leukemia UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies. Mother's immune system may block fetal treatments for blood diseases Pediatric researchers have resolved an apparent contradiction in the field of prenatal cell transplantation- a medical approach that holds future promise in correcting sickle cell disease and other serious congenital blood disorders. Methods for gene transfer in stem cells featured in Cold Spring Harbor Protocols Vectors derived from retroviruses are useful tools for long-term gene transfer because they allow stable integration of transgenes and propagation into daughter cells. Comprehensive look at rare leukemia finds relatively few genetic changes launch disease The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps. MGH study identifies first molecular steps to childhood leukemia A Massachusetts General Hospital (MGH)-based research team has identified how a chromosomal abnormality known to be associated with acute lymphoblastic leukemia (ALL) - the most common cancer in children - initiates the disease process. What do blood stem cells need to grow? Blood flow Blood stem cells literally go with the flow, according to a new report published as an immediate early publication in the journal Cell, a Cell Press journal, on May 13th. More Hematopoietic Current Events and Hematopoietic News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||